Boston Scientific Schedule of Major Presentations at Transcatheter Cardiovascular Therapies 2012 Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics...

NATICK, Mass. , Oct. 18, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) is scheduled to present sponsored research at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, which takes place October 22 – 26 in Miami , Florida. The clinical presentations will provide new insights on Boston Scientific research in coronary and peripheral artery disease, including aortic valve disease and atrial fibrillation.

Schedule of Events All programs are Eastern Daylight Time, with events held at the Miami Beach Convention Center unless otherwise indicated.

Tuesday, October 23

Wednesday, October 24

The Boston Scientific Technology Showcase will immediately follow from 8:30 p.m. to 10:00 p.m.

Conference attendees are invited to view "technologies that transform tomorrow and products that perform today" from Boston Scientific at booth 272 in the main exhibit hall.

The WATCHMAN, SYNERGY and Lotus devices are investigational devices and not available for sale in the United States .

About Boston Scientific Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com .

Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials and outcomes, our technology, product performance and importance, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

SOURCE Boston Scientific Corporation